These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9400524)

  • 1. Penile rigidity in erectile dysfunction treated with alprostadil.
    Greco E; Polonio-Balbi P
    Lancet; 1997 Dec; 350(9092):1682. PubMed ID: 9400524
    [No Abstract]   [Full Text] [Related]  

  • 2. [The therapeutic and diagnostic potentials of the intra-corpora cavernosa use of alprostadil, Edex, in patients with erectile dysfunction].
    Mzo EB; Dmitriev DG
    Ter Arkh; 1995; 67(10):45-8. PubMed ID: 8779105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracavernous injection as an option for aging men with erectile dysfunction.
    Wespes E
    Aging Male; 2002 Sep; 5(3):177-80. PubMed ID: 12471778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group.
    Linet OI; Ogrinc FG
    N Engl J Med; 1996 Apr; 334(14):873-7. PubMed ID: 8596569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors in predicting initial in-office therapeutic dosages of alprostadil for the treatment of organic impotence.
    Intili H
    Urol Nurs; 1998 Jun; 18(2):111-3. PubMed ID: 9866639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Penile shaft hypopigmentation: lichen sclerosus occurring after the initiation of alprostadil intracavernous injections for erectile dysfunction.
    English JC; King DH; Foley JP
    J Am Acad Dermatol; 1998 Nov; 39(5 Pt 1):801-3. PubMed ID: 9810901
    [No Abstract]   [Full Text] [Related]  

  • 7. Intraurethral application of alprostadil in patients with failed inflatable penile prosthesis.
    Benevides MD; Carson CC
    J Urol; 2000 Mar; 163(3):785-7. PubMed ID: 10687977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re: Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting.
    Hellstrom WJ; Lewis RW
    J Urol; 1999 Oct; 162(4):1390. PubMed ID: 10492215
    [No Abstract]   [Full Text] [Related]  

  • 9. [The use of PGE1 in the treatment of erectile deficiency].
    Arena F; Peracchia G; Di Stefano C; Cortellini P
    Acta Biomed Ateneo Parmense; 1996; 67(1-2):49-53. PubMed ID: 10021734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving erectile function. Incorporating new guidelines into clinical practice.
    Jensen PK; Lewis J; Jones KB
    Adv Nurse Pract; 2004 Apr; 12(4):40-9; quiz 50. PubMed ID: 15101134
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of transurethal alprostadil for safety and efficacy in men with erectile dysfunction.
    Kongkanand A; Ratana-Olarn K; Wuddhikarn S; Luengwattanakit S; Tantiwong A; Ruengdilokrat S; Opanuraks J; Sripalakit S
    J Med Assoc Thai; 2002 Feb; 85(2):223-8. PubMed ID: 12081123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of a needle-free high-pressure injection system with needle-tipped injection of intracavernosal alprostadil for erectile dysfunction.
    Harding LM; Adeniyi A; Everson R; Barker S; Ralph DJ; Baranowski AP
    Int J Impot Res; 2002 Dec; 14(6):498-501. PubMed ID: 12494285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Group B streptococcal septicemia following intracavernous injection therapy for erectile dysfunction in diabetes.
    Nalesnik JG; Jones L; Kraus SR
    J Urol; 2004 Jul; 172(1):151-2. PubMed ID: 15201758
    [No Abstract]   [Full Text] [Related]  

  • 14. Intraurethral alprostadil for impotence.
    Med Lett Drugs Ther; 1997 Mar; 39(997):32. PubMed ID: 9121395
    [No Abstract]   [Full Text] [Related]  

  • 15. Retention and migration of alprostadil cream applied topically to the glans meatus for erectile dysfunction.
    Yeager J; Beihn RM
    Int J Impot Res; 2005; 17(1):91-5. PubMed ID: 15538395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, placebo-controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan) for the in-office treatment of erectile dysfunction.
    Goldstein I; Payton TR; Schechter PJ
    Urology; 2001 Feb; 57(2):301-5. PubMed ID: 11182341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Transurethral alprostadil (MUSE) in erectile dysfunction].
    Comeri G; Gianneo E; Nespoli R
    Arch Ital Urol Androl; 1999 Sep; 71(4):249-51. PubMed ID: 10592541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re: Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting.
    Subramonian K; Weston PM
    J Urol; 1999 Jul; 162(1):168-9. PubMed ID: 10379774
    [No Abstract]   [Full Text] [Related]  

  • 19. Determinants of satisfactory rigidity after intracavernosal injection with prostaglandin E1 in men with erectile failure.
    Purvis K; Brekke I; Christiansen E
    Int J Impot Res; 1996 Mar; 8(1):9-16. PubMed ID: 8735188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction.
    Meinhardt W; de la Fuente RB; Lycklama à Nijeholt AA; Vermeij P; Zwartendijk J
    Int J Impot Res; 1996 Mar; 8(1):5-7. PubMed ID: 8735187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.